MK0524A Bioequivalence Study (0524A-059)

An Open Label, Randomized, 2-Period, Crossover Study to Establish the Definitive Bioequivalence of Niacin and MK0524 of 2 Sources of MK0524A Tablets

This study will evaluate the definitive bioequivalence of tablets of MK0524A (1000 mg Extended Release (ER) Niacin/ 20 mg laropiprant) from two sources.

Inclusion Criteria:

• Subject is in good health
• Subject is willing to follow all study guidelines

Exclusion Criteria:

• Subject has or has a history of any disease or condition that might confound the results of the study or make participation unsafe